

Agile Therapeutics

11:30 28 Oct 2019

Agile Therapeutics has productive 3Q as it lays the ground for commercialization of Twirla contraceptive patch

Agile Therapeutics Inc (NASDAQ:AGRX) CEO Al Altomari said Monday that the women's healthcare company was preparing for commercialization in the event that its lead product candidate, Twirla, an investigational prescription contraceptive is approved.

In a statement accompanying the Princeton, New Jersey-based women's healthcare company's latest numbers, Altomari said: "The third quarter of 2019 was another productive quarter for the company. We raised much needed cash to fund our business and allow us to reactivate Corium to prepare for commercialization in the event that Twirla is approved and to accomplish other precommercial activities."

Corium has the right to manufacture Twirla. Since September, Corium has been working with Agile to prepare facilities and equipment at its Grand Rapids manufacturing site for the commercial production of Twirla. It plans to kick off pre-validation work and Agile's goal is to manufacture three validation batches of Twirla. The Agile Therapeutics boss said the FDA has completed Corium's facility pre-inspection.

"Our team has been preparing to present the case for NDA (new drug application) approval of Twirla at the advisory committee meeting. We continue to believe that Twirla, if approved, will provide women with a new, important contraception option they do not currently have," said Altomari.

Executives from the company are expected to meet with the FDA's advisory committee on October 30 to review the NDA for Twirla, a low-dose prescription contraceptive delivered through the skin via the company's proprietary patch.

In parallel, Agile plans to work with managed care and patient payers to gain market access for Twirla in the first quarter of 2020.

"In the second quarter of 2020, the company plans to hire and train an initial sales team, which it estimates will be in the range of 50 to 90 persons," said the company.

Agile expects to ship product to wholesalers and start its commercial launch in the fourth quarter of 2020. The company's marketing efforts will initially focus on obstetrician-gynecologists in the US, and it plans to use a significant number of samples in the early stage of commercial launch to gain patient trial and acceptance.

Sufficient cash reserves

Agile said that as of September 30, it had \$18.4 million in cash and equivalents, compared to \$7.8 million in cash and equivalents on December 31, 2018. During the third quarter, the company boosted its cash position by raising \$12.7 million mainly from a sale of 14,526,315 shares through a public offering in August.

The company said it has enough cash on hand to meet its projected operating requirements through the end of the first

Price: 1.89

Market Cap: \$164.54 m

1 Year Share Price Graph



April 2019 October 2019 April 2020

Share Information

Code: AGRX

Listing: NASDAQ

52 week	High	Low
	4.75	0.35

Sector: Pharma & Biotech

Website: www.agiletherapeutics.com

Company Synopsis:

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our current product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.

action@proactiveinvestors.com

quarter of 2020. Agile will require additional capital to fund operating needs for the rest of 2020 and beyond, which will primarily be used for the completion of its commercial plan for Twirla.

For the third quarter ended September 30, the forward-thinking women's healthcare company posted a loss of \$4.4 million, or \$0.08 per share, compared to a net loss of \$3.8 million, or \$0.11 per share, in the same period a year earlier.

The company said research and development expenses were \$2.4 million for the third quarter, compared to \$1.5 million for the same period of 2018. The company explained that the rise in R&D expenses was linked to consulting fees paid to prep for the upcoming FDA advisory committee meeting later this month.

Research firm Oppenheimer predicts the Twirla contraceptive patch could drive sales of \$250 million to \$300 million.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Agile Therapeutics named herein, including the promotion by the Company of Agile Therapeutics in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).